Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03384524
Other study ID # The BEAT DME Study
Secondary ID
Status Withdrawn
Phase Phase 1/Phase 2
First received
Last updated
Start date March 2018
Est. completion date May 2019

Study information

Verified date March 2019
Source University of Southern California
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase I/II trial is designed to provide proof of concept evidence that combination therapy can have a beneficial effect on DME and possibly prevent increases in retinal volume or progression of non-central DME into the central subfield of the macula. If a beneficial effect is apparent in this phase I/II study involving a relatively small sample size and short follow-up period, its results could be used to in plan future phase III trials. We believe this study will be the first to show that a systems pharmacology approach can successfully address diabetic macular edema, and thus revolutionize the treatment of complex retinal diseases for which there are a paucity of effective treatment options.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date May 2019
Est. primary completion date May 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Age >18 years

- Type 1 or type 2 diabetes mellitus

- Best corrected visual acuity using the early treatment diabetic retinopathy study (ETDRS) visual acuity test letter score = 74 (i.e., 20/32 or better) within 30 days of enrollment.

- On clinical exam, definite retinal thickening due to DME within 3,000 µm of the center of the macula but not involving the 500 µm central subfield.

- Thickened non-central macular subfields on the spectral domain OCT macular map

- Central subfield thickness within threshold definition for normal central subfield thickness

- No focal/grid laser within the last 6 months or other treatment for DME within the last 4 months.

- Pseudophakia

Exclusion Criteria:

- Patients with active proliferative diabetic retinopathy

- Pan retinal photocoagulation within the last 12 months of study initiation

- A condition that, in the opinion of the investigator, would preclude participation in the study, e.g., unstable medical status including blood pressure, cardiovascular disease, and glycemic control.

- Subjects experiencing poor glycemic control who, within the last 4 months, initiated intensive insulin treatment (a pump or multiple daily injections) or plan to do so in the next 4 months.

- Use of systemic corticosteroids or anti-VEGF (vascular endothelial growth factor) therapy.

- Participation in an investigational trial that involves treatment with any drug within 30 days of randomization that has not received regulatory approval at the time of study entry.

Note: study participants cannot receive another investigational drug while participating in this study.

- Known allergy or hypersensitivity to any component of the study drugs.

- Postpartum women with a history of coronary artery disease or other severe cardiovascular conditions (a bromocriptine contraindication).

- Planned glaucoma surgery (floppy iris syndrome associated with tamsulosin therapy).

- Blood pressure > 180/110 mmHg (systolic above 180 or diastolic above 110 mmHg).

- If blood pressure is brought below 180/110 by anti-hypertensive treatment, an individual can become eligible.

- Subjects with second or third degree heart block (metoprolol contraindication).

- Subjects with asthma or other bronchospastic disease (metoprolol precaution).

- Individuals currently taking one of the study medications or a medication in the same therapeutic class (beta receptor antagonists, alpha-1 receptor antagonists, or bromocriptine).

- Participants expecting to move out of the area of the clinical center to an area not covered by another clinical center during the 12 months of the study.

- For women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next 12 months. Women who are potential study participants should be questioned about the potential for pregnancy. Investigator judgment will be used to determine when a pregnancy test is needed.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Bromocriptine 2.5 MG
Administered daily
Metoprolol 25 MG
Administered daily
Tamsulosin 0.4 MG
Administered daily
Other:
Placebo
Three pills, matching active drugs to be administered daily

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Andrew Moshfeghi, MD, MBA Case Western Reserve University

Outcome

Type Measure Description Time frame Safety issue
Primary Change in retinal volume Effects of bromocriptine/metoprolol/tamsulosin combination therapy on macular retinal volume compared with placebo in eyes with non-central diabetic macular edema (DME) 14 months
Secondary Progression of non-central DME compared to central DME Effects of therapy with bromocriptine/metoprolol/tamsulosin on central subfield thickness and compare the progression of non-central DME to central DME as determined by stereoscopic fundus photographs. 14 months
Secondary Progression of non-central DME compared to central DME Effects of therapy with bromocriptine/metoprolol/tamsulosin on central subfield thickness and compare the progression of non-central DME to central DME as determined by Optical Coherence Tomography (OCT). 14 months
Secondary Change in retinal density Measured by OCT-angiography 14 months
Secondary Foveal avascular changes Measured by fluorescein angiography. 14 months
See also
  Status Clinical Trial Phase
Completed NCT03953807 - A Study to Evaluate the Effectiveness and Safety of OZURDEX® in Patients With Diabetic Macular Edema But Never Treated Phase 4
Completed NCT03622580 - A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE) Phase 3
Recruiting NCT06262737 - Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol
Terminated NCT04603937 - A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) Phase 3
Terminated NCT04611152 - A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) Phase 3
Active, not recruiting NCT04108156 - This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Participants With Diabetic Macular Edema Compared With Intravitreal Ranibizumab Phase 3
Completed NCT02867735 - A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema Phase 1
Withdrawn NCT03629210 - Combination OZURDEX® & EyLea® vs. OZURDEX® Monotherapy in IncompLete-Responders wIth Diabetic Macular Edema Phase 2
Withdrawn NCT02842541 - Safety Study of Intravitreal EBI-031 Given as a Single or Repeat Injection to Subjects With Diabetic Macular Edema Phase 1
Completed NCT02221453 - Cytokine Levels in Patients With Persistent Diabetic Macular Edema Treated With Triamcinolone Acetonide Phase 2
Completed NCT02979665 - Changes to the Retina Following Anti-VEGF Treatments for Diabetic Macular Edema
Completed NCT02556723 - Intravitreal Injections of Ziv-aflibercept for Macular Diseases N/A
Completed NCT02000102 - Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab N/A
Completed NCT02088229 - Relating Retinal Structural and Functional Parameters to Visual Acuity in Eyes Undergoing Treatment for Diabetic Macular Edema N/A
Terminated NCT00779142 - Utility of Intravitreal Methotrexate in Diabetic Macular Edema Resistant to Conventional Therapies N/A
Completed NCT01171976 - Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus Phase 3
Completed NCT00989989 - Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema Phase 3
Completed NCT01259609 - Changes in Ciliary Body Thickness in Patients With Diabetic Macular Edema After Vitrectomy N/A
Terminated NCT00768040 - Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema Phase 2
Completed NCT00683176 - Effect of Choline Fenofibrate (SLV348) on Macular Edema Phase 2